Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | G6PD | P11413 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302820 | 0.92 | DNMT1 (0.43) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL6296568 | 0.79 | KMT2A (0.44) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL6296402 | 0.78 | DNMT1 (0.47) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL6381936 | 0.78 | TDP1 (0.40) | KMT2ADNMT1BCHEACHEGAA | |
| SCHEMBL8702569 | 0.77 | DNMT1 (0.46) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL5880835 | 0.76 | DNMT1 (0.45) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL8008611 | 0.76 | DNMT1 (0.45) | KMT2AMEN1DNMT1BCHEACHE | |
| Hydrochloric Acid SCHEMBL5880769 | 0.75 | DNMT1 (0.44) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL7363568 | 0.73 | NR4A2 (0.40) | KMT2AMEN1DNMT1BCHEACHE | |
| SCHEMBL6302892 | 0.73 | KDM4E (0.52) | KMT2AMEN1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | claimed |
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | KMT2A 2939/4885MEN1 3684/4885DNMT1 3820/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | KMT2A 2859/4885MEN1 3519/4885DNMT1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.